Blocking human enterovirus 71 replication by targeting viral 2A protease | Zendy

Nisrine Falah | Zendy; Roland Montserret | Zendy; Virginie Lelogeais | Zendy; Isabelle Schuffenecker | Zendy; Bruno Lina | Zendy; Jc Cortay | Zendy; Sébastien Violot | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Blocking human enterovirus 71 replication by targeting viral 2A protease

Author(s) -

Nisrine Falah,

Roland Montserret,

Virginie Lelogeais,

Isabelle Schuffenecker,

Bruno Lina,

Jc Cortay,

Sébastien Violot

Publication year - 2012

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dks304

Subject(s) - peptide , viral replication , isothermal titration calorimetry , virology , protease , biology , microbiology and biotechnology , chemistry , biochemistry , virus , enzyme

Human enterovirus 71 (EV-71), a member of the Enterovirus genus, constitutes a major public health issue in the Asia-Pacific region, where it is associated with several severe neurological complications. There is currently no effective vaccine or antiviral against EV-71. The aim of this study was to determine whether the six amino acid peptide LVLQTM, which was previously shown to inhibit human rhinovirus (HRV) 2A protease (2A(pro)) activity in vitro and HRV replication in vivo in mice, could be of more general use against enteroviruses and more particularly against EV-71.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research